Case number 2017-2202
Horizon Pharma Ireland v. Actavis Laboratories UT, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 3, 2020 | 6 | Mandate issued to the United States District Court for the District of New Jersey. Service as of this date by the Clerk of Court. [675872] [17-2149, 17-2152, 17-2153, 17-2202, 17-2203, 17-2206] [JAB] [Entered: 03/03/2020 01:50 PM] (1) |
| Oct 10, 2019 | 4 | OPINION filed for the court by Prost, Chief Judge; Newman, Circuit Judge and Reyna, Circuit Judge. Opinion concurring in part and dissenting in part filed by Circuit Judge Newman. Precedential Opinion. [641453] [17-2149, 17-2152, 17-2153, 17-2202, 17-2203, 17-2206] [JAB] [Entered: 10/10/2019 09:50 AM] (55) |
| Oct 10, 2019 | 5 | JUDGMENT. AFFIRMED. Terminated on the merits after oral argument. COSTS: No Costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [641454] [17-2149, 17-2152, 17-2153, 17-2202, 17-2203, 17-2206] [JAB] [Entered: 10/10/2019 09:51 AM] (2) |
| Jul 19, 2017 | 3 | ORDER granting motion to consolidate appeals [446747-2] filed by Cross-Appellant Actavis Laboratories UT, Inc. and Appellants Horizon Pharma USA, Inc., Horizon Pharma Ireland Limited and HZNP Limited in 17-2149; Appellants’ opening brief is due no later than August 14, 2017. All remaining deadlines are to be calculated in accordance with Federal Circuit Rule 31(a). Service: 07/19/2017 by clerk. [447715] [17-2149, 17-2152, 17-2153, 17-2202, 17-2203, 17-2206] [NL] [Entered: 07/19/2017 03:40 PM] (2) |
| Jun 22, 2017 | 1 | Appeal docketed. Received: 06/19/2017. [441301]. [FMS] [Entered: 06/22/2017 10:33 AM] (37) |
| Jun 22, 2017 | 2 | Note to file: The following cases are associated:17-2149 Lead with 17-2202 Cross-Appeal. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [441303] [17-2149, 17-2202] [FMS] [Entered: 06/22/2017 10:36 AM] (0) |
